Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mirum Pharmaceuticals, Inc.

45.99
-0.0900-0.20%
Post-market: 45.990.00000.00%18:21 EDT
Volume:155.89K
Turnover:7.18M
Market Cap:2.25B
PE:-24.85
High:46.52
Open:46.44
Low:45.79
Close:46.08
Loading ...

Company Profile

Company Name:
Mirum Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
322
Office Location:
950 Tower Lane,Suite 1050,Foster City,California,United States
Zip Code:
94404
Fax:
- -
Introduction:
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Directors

Name
Position
Christopher Peetz
President and Chief Executive Officer and Director
Michael Grey
Chairman of the Board
Laura Brege
Director
Laurent Fischer
Director
Lon Cardon
Director
Niall O'Donnell
Director
Patrick Heron
Director
Saira Ramasastry
Director
Timothy Walbert
Director
William Fairey
Director

Shareholders

Name
Position
Christopher Peetz
President and Chief Executive Officer and Director
Peter Radovich
Chief Operating Officer
Lara Longpre
Chief Development Officer
Pamela Vig
Head of Research and Development